Shadmehr Elham, Hashemi Sara, Hashemi Seyed Saman, Chung Yoo Jung, Goudarzi Arman, Khademi Abbasali
Department of Endodontics and Periodontics, Division of Endodontics, School of Dentistry, University of California, San Francisco, USA.
Dental Students' Research Committee, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.
Iran Endod J. 2021 Fall;16(4):210-216. doi: 10.22037/iej.v16i4.33555.
Articaine is reported to have a fast onset and a short-acting pulpal anesthesia in inferior alveolar nerve blocks. Clonidine is an -adrenoceptor agonist and is used as an adjunct to enhance the anesthetic efficacy and induce greater analgesia. In an attempt to search for more effective ways to achieve profound analgesia after root canal treatment, this randomized clinical trial assessed the efficacy of clonidine added to articaine/epinephrine solution on post-operative pain relief after root canal treatment in mandibular molars with irreversible pulpitis.
Our randomized clinical trial study enrolled one hundred patients with symptomatic irreversible pulpitis in mandibular molars. They were divided into two groups, each group received either 0.2 mL 150 µg/mL clonidine or distilled water added to 1.8 mL of 4% articaine with 1:100,000 epinephrine cartridge. The alveolar nerve block in the two groups was administered by the same clinician and the subject's pain scores were recorded at 6, 12, 24, 48 and 72 h post-operatively using a Heft-Parker visual analog scale. Data were analyzed using t, chi-square and repeated-measures ANOVA statistical tests.
The mean pain scores for clonidine group were significantly lower than control at all the time intervals after treatment (<0.05). We did not notice any clinical and there were no complaints from the patients either.
Based on this randomized clinical trial study the addition of clonidine to the articaine/epinephrine solution using an inferior alveolar nerve block during root canal treatment in mandibular molars with irreversible pulpitis may be effective in reducing post-operative pain.
据报道,阿替卡因在下牙槽神经阻滞中起效快且牙髓麻醉作用时间短。可乐定是一种α-肾上腺素能受体激动剂,用作辅助药物以增强麻醉效果并诱导更强的镇痛作用。为了寻找在根管治疗后实现深度镇痛的更有效方法,本随机临床试验评估了在患有不可逆性牙髓炎的下颌磨牙根管治疗中,将可乐定添加到阿替卡因/肾上腺素溶液中对术后疼痛缓解的疗效。
我们的随机临床试验研究纳入了100例有症状的下颌磨牙不可逆性牙髓炎患者。他们被分为两组,每组接受0.2 mL 150μg/mL可乐定或加入1.8 mL含1:100,000肾上腺素的4%阿替卡因药筒中的蒸馏水。两组的牙槽神经阻滞均由同一名临床医生实施,术后6、12、24、48和72小时使用Heft-Parker视觉模拟量表记录受试者的疼痛评分。使用t检验、卡方检验和重复测量方差分析统计检验对数据进行分析。
治疗后的所有时间间隔,可乐定组的平均疼痛评分均显著低于对照组(P<0.05)。我们未观察到任何临床问题,患者也无任何主诉。
基于这项随机临床试验研究,在患有不可逆性牙髓炎的下颌磨牙根管治疗期间,在下牙槽神经阻滞中向阿替卡因/肾上腺素溶液中添加可乐定可能有效减轻术后疼痛。